Cell plasticity in cancer cell populations

Shen, Shensi; Clairambault, Jean

doi:10.12688/f1000research.24803.1

Cited by 62 publications

(46 citation statements)

References 127 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It can be exploited for therapeutic purposes, as exemplified by recent studies. This could be achieved by directly inhibiting the mediators of lineage plasticity as seen in prostate cancer and basal cell carcinoma [204][205][206] or by direct targeting of the cancer cells exhibiting plasticity [144,205]. The involvement of epigenetic modulators in regulating lineage plasticity makes reversal of the plasticity another plausible therapeutic option ( [207]).…”

Section: Therapeutic Targeting Of Lineage Plasticity -Taming the Shape Shiftermentioning

confidence: 99%

See 1 more Smart Citation

Lineage Plasticity in Cancer: The Tale of a Skin-walker

Thankamony¹,

Subbalakshmi²,

Jolly³

et al. 2021

Preprint

View full text Add to dashboard Cite

Lineage plasticity, the switching of cells from one lineage to another has been recognized to be a cardinal property essential for embryonic development, tissue repair and homeostasis. However, such a highly regulated process goes awry when cancer cells exploit this inherent ability to their advantage, resulting in tumorigenesis, relapse, metastasis and therapy resistance. In this review, we summarize our current understanding on the role of lineage plasticity in tumor progression and therapeutic resistance in multiple cancers. Lineage plasticity can be triggered by treatment itself and is reported across various solid as well as liquid tumors. Here we focus on the importance of lineage switching in tumor progression and therapeutic resistance of solid tumors such as the prostate, lung, hepatocellular and colorectal carcinoma and the myeloid and lymphoid lineage switch observed in leukemias. Besides this, we also discuss the role of Epithelial-Mesenchymal Transition (EMT) in facilitating the lineage switch in biphasic cancers such as aggressive carcinosarcomas. We also discuss the mechanisms involved, current therapeutic approaches and challenges that lie ahead in taming the scourge of lineage plasticity in cancer.

show abstract

Section: Therapeutic Targeting Of Lineage Plasticity -Taming the Shape Shiftermentioning

confidence: 99%

“…Since TME is also a critical regulator of cellular plasticity, targeting the TME components along with the cancer cells is an attractive strategy to combat the cancer plasticity [205,213].…”

Section: Therapeutic Targeting Of Lineage Plasticity -Taming the Shape Shiftermentioning

confidence: 99%

Lineage Plasticity in Cancer: The Tale of a Skin-walker

Thankamony¹,

Subbalakshmi²,

Jolly³

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Phenotype switching, or more generally continuous phenotype-determined cell plasticity, is an essential process originally observed during development, but is also now recognised as an important phenomenon upon injury and disease. One of the best described examples of phenotypic switching in cancer depends on the process of epithelial to mesenchymal transition (EMT) and its reversion (MET) [11]. In the context of anti-cancer therapies, cell plasticity enables tumour cells to change to a cell phenotypic identity that may be dependent or not on the drug target, without additional secondary genetic mutations.…”

Section: Non Genetic Phenotype Switchingmentioning

confidence: 99%

Plasticity in Cancer Cell Populations: Biology, Mathematics and Philosophy of Cancer

Clairambault¹

2020

Mathematical and Computational Oncology

Self Cite

View full text Add to dashboard Cite

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

show abstract

“…These strategies, which are still theoretical, may be too recent to be widely accepted by oncologists as plausibly efficacious and challenged by preliminary experiments, in Petri dishes or in laboratory rodents. In the meantime, many questions arise about the nature of plasticity in cancer cells and cancer cell populations that underly them (reviewed in Shen and Clairambault, 2020 ). Cancer is a disease of multicellular organisms that are normally functionally constituted of terminally and irreversibly differentiated cells.…”

Section: Modeling Plasticity In Cancer Cell Populationsmentioning

confidence: 99%